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Abstract
It is extremely rare for a single experiment to be so impactful and timely that it shapes and 
forecasts the experiments of the next decade. Here, we review how two such experiments --the 
generation of human induced pluripotent stem cells (iPSCs) and the development of CRISPR/Cas9 
technology-- have fundamentally reshaped our approach to biomedical research, stem cell biology 
and human genetics. We will also highlight the previous knowledge that iPSC and CRISPR/Cas9 
technologies were built on as this groundwork demonstrated the need for solutions and the benefits 
that these technologies provided, and have set the stage for their success.
Reprogramming: “The Yamanaka experiment”
Ten years ago Takahashi and Yamanaka reported on the “Induction of Pluripotent Stem Cells 
from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors” (Takahashi and 
Yamanaka, 2006). The hypothesis of this work was daring and stated that a small set of 
transcription factors, when ectopically expressed in a somatic cell, can reprogram them back 
into a pluripotent state. Retrospectively, the simplicity of the experiments that Yamanaka and 
colleagues used to test this hypothesis were beautiful: take a set of 24 candidate genes, 
selected mostly for their high and specific expression in pluripotent cells, and 
simultaneously express them in differentiated cells using integrating retroviruses. Identify 
cells that induced pluripotency via a selectable marker gene that is not expressed in somatic 
cells, but is preferentially activated in pluripotent cells. Next, narrow down the cocktail of 
genes to the minimal set of reprogramming factors (Klf4, Sox2, Oct4 and Myc, a.k.a. 
KSOM) by process of elimination. Lastly, demonstrate that the resulting induced pluripotent 
cells have all the key features of their embryonic stem cell counterparts, such as a stem cell-
like expression profile, the ability to give rise to differentiated cells in teratoma formation 
assays and their contribution to tissues in chimeric mice after blastocyst injections 
(Takahashi and Yamanaka, 2006).
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These experiments had an immediate impact. They came at a time when the potential of 
pluripotent stem cells in research applications and regenerative medicine had widely been 
appreciated (Rideout et al., 2002) (Figure 1), but technical and ethical limitations presented a 
challenge that severely impeded major progress towards realizing their full potential. 
Decades before the study by Yamanaka, John Gurdon (Gurdon, 1962, 1963) had 
demonstrated that the epigenetic profile of a fully differentiated cell can be reprogrammed to 
a pluripotent state. From a set of key experiments Gurdon demonstrated that a nucleus taken 
from a differentiated frog cell and injected into an enucleated oocyte can gives rise to a fully 
developed frog. This experiment illustrated that during differentiation no essential genetic 
material is lost and secondly that the epigenetic changes that drive cellular differentiation 
can be reprogrammed to totipotency. Decades later, the cloning of the sheep “Dolly” also by 
somatic cell nuclear transfer (SCNT) demonstrated that Gurdon’s finding extended to 
mammals as well (Campbell et al., 1996). SCNT and cell fusion experiments gave two 
additional insights that set the stage for the Yamanaka experiment. First, they demonstrated 
that the cytoplasm of an oocyte or an ESC contained diffusible transacting factors capable of 
reprogramming a somatic nucleus (reviewed in (Ambrosi and Rasmussen, 2005)). Second, 
successful derivation of mice by SCNT with nuclei of B-cells as a donor, which had 
undergone VDJ-recombination, provided genetic evidence that terminally differentiated cells 
can be reprogrammed (Hochedlinger and Jaenisch, 2002). Though more challenging, SCNT 
was eventually successful in reprogramming human cells into hESCs in 2014 (Yamada et al., 
2014). While these experiments spoke for the possibility of cellular reprogramming, they 
also suggested highly sophisticated machinery and a complex biological process, making the 
success of the basic Yamanaka experimental approach even more astounding. Even today, 
the gradual pace of transcription factor-mediated reprogramming remains one of the most 
fascinating facets of the Yamanaka experiment: epigenetic changes after fertilization as well 
as reprogramming by SCNT occur within a few hours, while reprogramming by the 
Yamanaka experiment requires significantly more time, generally several days and multiple 
cell divisions. Yet, both processes result in a functionally equivalent cellular pluripotent state 
in in vitro cultures that is capable of forming an entirely new organism.
Around the same time as the first mammalian SCNT efforts, James Thomson derived the 
first human embryonic stem cell lines (Thomson et al., 1998). He used a very similar 
strategy that had proven successful for Evans and Martin (Evans and Kaufman, 1981; 
Martin, 1981), culturing the inner cell mass outgrowth of explanted blastocysts. However, it 
is interesting to note that human and mouse embryonic stem cell maintenance requires 
distinct signaling networks and culture conditions. LIF/Stat3 is required for maintaining the 
undifferentiated state in mESCs and BMP4 can inhibit the MEK/ERK differentiation 
pathway resulting in mESC self-renewal. In contrast hESCs and hiPSCs do not require hLIF, 
and maintenance of pluripotency seems to rely mostly on FGF and MEK/ERK signaling 
indicating species-specific requirements for culturing pluripotent cells. It seems likely that 
this difference can be attributed to a difference in the developmental stage that is captured in 
vitro from the outgrowth of the inner cell mass, where hPSCs cultured under standard 
conditions represent a later epiblast-like pluripotent state (Brons et al., 2007; Tesar et al., 
2007; Theunissen et al., 2014) and (reviewed in (Nichols and Smith, 2009).
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Proof of concept experiments with cells differentiated from hESCs suggested that 
pluripotent stem cells could be a source for cell replacement transplantation therapies and 
could provide a model system to understand early human development and cellular 
differentiation. However, ethical concerns, limited access to embryos, and the possibility of 
immune rejection were roadblocks that impeded the promise of hESCs.
In 2006 the “Yamanaka experiments” made the ethical debate about pluripotent stem cell 
research largely obsolete, as they established a robust method to derive human pluripotent 
cells without the use of human embryos. Furthermore iPSC technology promised to solve 
complications that were anticipated from immune rejections of heterologous hESC-derived 
tissues, as it would allow for the generation of patient-specific autologous pluripotent cells 
and derived tissue. The race to perform the key functional follow-up experiments began 
immediately. For the mouse system it was essential to establish that iPSCs could pass the 
most stringent test for pluripotency: germ line transmission (Maherali et al., 2007; Okita et 
al., 2007; Wernig et al., 2007) and tetraploid complementation (Kang et al., 2009; Zhao et 
al., 2009).
For the human system the initial question was whether the same set of factors capable of 
reprogramming mouse cells would also work for human cells (Takahashi et al., 2007). 
Yamanaka and Takahashi quickly demonstrated that their factors also worked in human cells 
(Takahashi et al., 2007). However, additional experiments over that last ten years in mouse 
and human cells also revealed that other sets of transcription factor combinations can be 
equally potent in reprogramming cells to a pluripotent state, providing valuable insights into 
the transcriptional pluripotency networks and how cells establish pluripotency (Buganim et 
al., 2012) (Apostolou and Hochedlinger, 2013; Park et al., 2008; Takahashi and Yamanaka, 
2015; Yu et al., 2007).
For the anticipated clinical application of iPSCs it was important to demonstrate that 
reprogramming could be achieved without stably integrating the KSOM factors into the 
genome of the somatic cell. Such factor-free iPSCs were generated by independent methods 
such as the excision of reprogramming factors using the Cre/LoxP (Soldner et al., 2009) or 
the piggyBack system (Kaji et al., 2009; Woltjen et al., 2009), by avoiding integration of the 
reprogramming factors all together using non-integrating viruses (Fusaki et al., 2009), 
episomal vectors (Yu et al., 2009) or direct transfection of the reprogramming factors as 
either mRNA (Warren et al., 2010) or protein (Kim et al., 2009). Initially, human cell 
reprogramming was quite inefficient compared to mouse cells, and thus several technical 
improvements were made to optimize hiPSC reprogramming protocols, culture conditions 
and iPSC characterization procedures to test for the pluripotency of newly isolated iPSCs. 
Eventually, these optimizations made iPSC technology increasingly more accessible to 
laboratories without previous stem cell experience and are now so streamlined that iPSC 
derivation, maintenance and differentiation are a widely used research tool in all aspects of 
biomedical research. In addition, efficient and robust reprogramming techniques provided 
insight into the mechanistic steps of reprogramming and the order of events involved in 
reverting the epigenome from a differentiated to a pluripotent state. A detailed understanding 
of the forces at work is necessary to answer the key questions of whether reprogramming of 
human cells results in a cell state that is equivalent to human embryonic stem cells or 
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whether iPSCs retain to some extent an epigenetic memory (Kim et al., 2010; Polo et al., 
2010). For example, do iPSCs derived from liver cells retain some characteristics of liver 
cells and do they preferentially differentiate into liver tissue relative to other cell types? 
Tetraploid complementation and germ line transmission experiments gave the clear answers 
that mouse iPSCs were fully reprogrammed to pluripotency. However these tests are not 
available for hiPSCs. Moreover, it is not clear to what extent the miPSC’s epigenome is reset 
during the reprogramming process and how much of the resetting occurs in vivo or when the 
cells pass through the germ line. It is not surprising that early cellular stages of the 
reprogramming process will show epigenetic differences, yet all these differences eventually 
will converge on the same pluripotent cell state as ESCs. Thus, it is interesting to further 
examine the level and functional relevance of epigenetic memory; yet it seems that such 
epigenetic differences in cellular state are at best small and overshadowed by differences 
caused by the reprograming method of choice, cell selection during propagation, culture 
conditions, and more importantly genetic background of the parental somatic cell (Guenther 
et al., 2010; (Kyttala et al., 2016); (Rouhani et al., 2014)). For example, it has been 
demonstrated that the epigenetic memory, i. e. epigenetic characteristics reflecting the state 
of the donor cells seen initially in the iPSCs, is lost upon prolonged cell passages suggesting 
that this donor cell-specific memory may be of little functional relevance (Polo et al., 2010).
The most attractive application of the iPSC technology is that it allows the isolation of 
patient-derived cells that carry all genetic alterations that cause the particular disease. Thus, 
these cells provide an experimental system to study pathogenesis of the disease in an in vitro 
system and to possibly devise therapeutic strategies (Robinton and Daley, 2012). 
Importantly, the iPSC technology allows comparison of the neuroanatomical features, and 
physiology of the iPSCs to the clinical features of the donor patient.
The power and limitations of iPSCs
In addition to the prospect of future iPSC-based cell replacement therapies, the ability to 
derive iPSCs from patients’ cells had a striking effect on human disease modeling. Some of 
the most remarkable advances were made in diseases such as neurodegenerative diseases 
that are only partially recapitulated in animal models. Here, iPSC technology was 
particularly transformative, as it made it possible to study the effects of familial monoallelic 
diseases as well as complex idiopathic diseases in the context of patient-derived neurons and 
tissue, systems that were previously not readily available for experimental investigation. For 
example, studying dopaminergic neurons differentiated from patient derived iPSCs yielded 
insights into the molecular causes of the disease and the identification of cellular stressors 
that might exacerbate the phenotype (Soldner et al, 2011, 2012);. As a result of such 
advances, iPSC-based and primary tissue culture systems have largely replaced previous 
experimental systems that studied human genetic diseases using overexpression studies in 
cancer cell lines. Indeed, the number of human diseases modeled in culture using patient 
derived iPS cells (“disease in the dish”) is growing rapidly (summarized in (Avior et al., 
2016; Sterneckert et al., 2014)).
While the approach of studying human disease in the disease-relevant cell type resulted in 
many success stories and insights, several challenges of iPSC disease modeling quickly 
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became apparent. For one, it became evident that many protocols that were developed for the 
differentiation of hPSCs into functional tissue resulted in embryonic rather than adult human 
cell types (Bedada et al., 2015; Forster et al., 2014; Hrvatin et al., 2014; Spence et al., 2011; 
Takebe et al., 2013). This observation might not pose a problem for studies that aim to 
recapitulate cell-autonomous defects of developmental diseases that likely will become 
apparent after a few weeks of in vitro differentiation. However, iPSC differentiation 
experiments that aim to understand human disease and pathologies within the context of the 
adult or as a function of human aging suffer from a lack of cellular maturity as well as a 
relatively short timespan limited by culture conditions. One approach to increase the 
maturity of in vitro cell systems and to mimic cellular aging is to expose these cells to 
stressors that are associated with aging (Miller et al., 2013; Studer et al., 2015). Significant 
progress has also been made to current strategies of investigating cell non-autonomous 
biological problems, including the development of co-culture experiments and protocols to 
differentiate hPSCs into tissue stem cells and organoid cultures. Organoid cultures are small 
functional tissue units comprised of several distinct cell types that can be maintained and 
used to recapitulate features of tissues rather than that of individual cell types in vitro 
(Lancaster et al., 2013; Sato et al., 2011; Sato et al., 2009) (reviewed in (Lancaster and 
Knoblich, 2014) (Sato and Clevers, 2013).
An important and often ignored challenge of iPSC technology is the variability between 
individual iPSC lines in their potential to differentiate into functional cells of a given 
lineage. This variation between cell lines is unpredictable and mostly caused by genetic 
background differences as well as the reprogramming history of a given cell line. Thus, in 
efforts to model a disease, detection of small phenotypic differences between cells 
differentiated from a patient or control iPSCs may not reveal a disease-relevant phenotypic 
difference but rather reflect the system’s immanent variation between individual iPSC lines 
(Soldner and Jaenisch, 2012). The generation of isogenic pairs of disease-specific and 
control iPSCs that differ exclusively at the disease-causing mutation has been used to control 
for the variation and have lead to defining subtle disease-relevant differences in monogenic 
diseases (Soldner et al, 2011). The problem is, however, exacerbated when studying more 
clinically important sporadic or polygenic diseases where low effect size disease-causing 
loci are defined by genome wide association studies (GWAS). Since phenotypic differences 
would be expected to be small, the use of isogenic pairs of disease-specific and control cells 
would be even more important. Finally, ongoing efforts to learn about human genetic 
variation by studying dozens or even hundreds of iPSC lines derived from healthy donors 
may give little interpretable information because of the unpredictable system-inherent 
phenotypic variability between individual iPSC lines (differing in millions of SNPs within 
each genome) and experimental variations in their differentiation. Making isogenic iPSC 
controls by genome editing that differ only in single or few SNPs could reduce variations 
due to genomic variability.
The challenge associated with the genetic variability of hPSCs is compounded by another 
remarkable difference between mouse and human pluripotent stem cells: the striking 
resilience of hPSCs to conventional gene targeting approaches. This dearth of genetic 
control in hPSCs prevented genetic experiments that were considered standard in mouse 
embryonic stem cells. Nevertheless conventional gene targeting has been accomplished in 
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hPSCs (Zwaka and Thomson, 2003). Protocols for conventional gene targeting have been 
optimized to modify human pluripotent stem cells (Costa et al., 2007; Davis et al., 2008a; 
Irion et al., 2007; Ruby and Zheng, 2009) and have been successfully used to establish hPSC 
models for human disease such as Lesch-Nyhan syndrome (Urbach et al., 2004). Moreover, 
this approach has been used to correct the disease-causing mutation with ornithine-d-
aminotranferase that is mutated in patients with gyrate atrophy (Howden et al., 2011), or to 
alter the amount of disease-causing CAG repeat expansions in the huntingtin gene of patient-
specific iPSCs (An et al., 2012). Furthermore, these protocols have been used to generate 
linage reporters for genes such as MIXL and Olig2 to study cell fate decision of 
differentiating human stem cells (Davis et al., 2008b; Xue et al., 2009). Overall however, 
these approaches are very time consuming, as they generally require the generation of large 
targeting constructs and even then are very inefficient and in many cases not successful. It 
appears that cell-intrinsic features such as low homologous recombination and single-cell 
survival rates make conventional genome modification as described by Capecchi and 
Smithies for mESCs (Doetschman et al., 1987; Thomas and Capecchi, 1987) very inefficient 
in hPSCs.
Both of these challenges have been overcome: the development of the Rho-kinase inhibitor 
Y-27632 to suppress anoikis during the disaggregation of hPSC colonies dramatically 
increased single-cell survival of hPSCs (Watanabe et al., 2007). The low frequency of 
spontaneous homology mediated gene targeting in hPSCs was dramatically increased 
through the development of site-specific nucleases (SSN) as a tool for their genetic 
engineering (reviewed in (Carroll, 2014; Hsu et al., 2014; Urnov et al., 2010)).
Genome editing BC (before CRISPR/Cas9)
The development of SSNs as research tools parallels the development of iPSCs: key 
experiments uncovered the biological principles and highlight how a generalized platform 
for genome editing would advance basic and biomedical research. Repurposing of the 
CRISPR/Cas9 system as an engineered SSN removed the impediments that limited the full 
potential of genome editing by providing this general platform.
Key experiments more than 15 years ago in mammalian cells demonstrated that a double 
strand break (DSB) generated by a SSN at a defined genomic site can be repaired either by 
the endogenous homology-mediated repair machinery using an exogenous provided repair 
template or by the error-prone Non-homologous end joining (NHEJ)-DNA repair pathway 
(Rouet et al., 1994a, b). The crucial observation made during these experiments was that a 
DSB increased the rate of homology-mediated genomic changes at the break site by several 
orders of magnitude compared to conditions in which only an exogenous repair template 
was provided without the induction of a DSB. Importantly, this principle of employing a 
DSB to facilitate DNA-repair mediated editing of genomes proved to be almost universal 
and applies to hPSCs as well as other systems such as C. elegans (Morton et al., 2006; Wood 
et al., 2011) and Drosophila melanogaster (Beumer et al., 2008; Bibikova et al., 2003; 
Bibikova et al., 2002), which are similarly resilient to conventional gene-targeting strategies 
as hPSCs.
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Already in 2005, Urnov et al. demonstrated that engineered zinc finger nucleases (ZFN) can 
serve as a designer SSN to correct X-linked SCID disease-relevant mutations in patient-
specific cells (Urnov et al., 2005). It was this study that coined the term “genome editing”. 
Ten years later the first clinical trials based on this ZFN technological platform are 
underway to disrupt CCR5 in T cells to treat HIV patients (Tebas et al., 2014).
Based on these pioneering experiments, we and others implemented the use of SSNs such as 
ZFNs and transcription activator like effector nucleases (TALENs) to engineer hPSCs 
(DeKelver et al., 2010; Hockemeyer and Jaenisch, 2010; Hockemeyer et al., 2009; 
Hockemeyer et al., 2011; Lombardo et al., 2007; Sexton et al., 2014; Soldner et al., 2011; 
Zou et al., 2009). These experiments provided proof of principle for SSN-mediated gene 
knockouts, for the insertion of transgenes into expressed and non-expressed genes to 
generate cell type-specific lineage reporters, for the over expression of transgenes from 
genetically defined loci, and for the insertion or repair of disease-relevant point mutations in 
hPSCs (Figure 2).
The technical advances that established genetic control in hPSCs proved to be highly 
synergistic with the development of iPSC technology. Genome editing in hPSCs overcame 
the issue of enormous genetic background variability inherent to iPSC-based disease models. 
Independent proof of concept studies demonstrated that SSNs can be used to repair or 
introduce disease relevant mutations in hPSCs (Soldner et al., 2011; Yusa et al., 2011). The 
resulting pairs of pluripotent stem cell lines are isogenic, except for the disease-relevant 
mutation. Parallel differentiation of such isogenic sets of cells into disease-relevant cells and 
tissues can be used to directly assess the contribution of a mutation to cellular pathology 
(Chung et al., 2013; Ryan et al., 2013; Wang et al., 2014b; Yusa et al., 2011).
The initial ZFN and TALEN platforms to generate SSNs for genome editing in stem cells 
were costly and labor-intensive and their implementation as research tools therefore 
developed comparatively slowly. However, extensive work with ZFNs and TALENs has 
demonstrated the power of genome editing and highlighted the impact that a universal, 
cheaper, and simpler platform to make SSNs would have.
CRISPR/Cas9: everyone can edit anything
The need for a simple and unified platform to generate SSNs was met and resolved, 
similarly to the need for an easy way to make iPSCs, through a single experiment: by 
repurposing the bacterial Clustered regularly interspaced short palindromic repeats 
(CRISPR)/CRISPR-associated (Cas) adaptive immune systems (reviewed in (Marraffini, 
2015) as a SSN. In 2012 the collaborative work of the Jennifer Doudna and Emmanuelle 
Charpentier laboratories demonstrated that in CRISPR type-2 systems a single protein, Cas9, 
can function as a designer SSN, by associating with an engineered single guide RNA 
(sgRNA) that bears homology to a genetic locus of interest (Jinek et al., 2012). In this 
process, the sgRNA substitutes the natural Cas9-associated bacterial RNAs that normally 
confer target specificity for the bacterial pathogen DNA, and instead directs Cas9 to 
introduce a blunt DSB in any target DNA with complementarity to a 20nt long sequence in 
the sgRNA. Doudna and colleagues predicted that this simple way of engineering SSNs 
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could be exploited to streamline genome editing (Jinek et al., 2012). In less than four years 
this prediction became reality and Cas9-mediated genome engineering was developed into 
the platform of choice to generate SSNs and to genetically modify hPSCs (Chen et al., 2015; 
Cong et al., 2013; Fu et al., 2014; Gonzalez et al., 2014; Gu et al., 2015; Hou et al., 2013; 
Hsu et al., 2014; Kleinstiver et al., 2016; Liao and Karnik, 2015; Lin et al., 2014; Mali et al., 
2013; Ran et al., 2015; Slaymaker et al., 2016; Tsai et al., 2014; Wu et al., 2014b). Some 
important adaptations and improvements to increase the ease and scope of Cas9-mediated 
genome engineering in hPSCs was the establishment of CRISPR/CAS-systems from 
different organisms (Hou et al., 2013; Zetsche et al., 2015) that respond to different PAM 
sequences or by engineering spCas9 to associate with alternative PAMs by structure-based 
engineering of Cas9 and thereby extending genomic target range and specificity of spCas9 
(Kleinstiver et al., 2015a; Kleinstiver et al., 2015b). Furthermore, several detailed protocols 
that describe the implementation of genome editing techniques in pluripotent stem cell 
systems have been optimized and published (Blair et al., 2016; Byrne and Church, 2015; 
Chiba and Hockemeyer, 2015; Yusa, 2013).
The key advantage of the CRISPR/Cas9 system over previous systems lies in the fact that 
DNA-binding specificity is encoded solely by the sgRNA and so unlike previous platforms 
does not require laborious engineering of DNA binding proteins. Thus CRISPR/Cas9-based 
editing has largely replaced previous SSN technologies. Combining the cellular versatility of 
iPSC differentiation with the ease of CRISPR/Cas9-mediated genome editing proved to be a 
very powerful experimental approach and by now genome editing in hPSCs has become a 
standard tool in stem cell research and human disease modeling (Johnson and Hockemeyer, 
2015; Matano et al., 2015; Schwank et al., 2013).
One of the most exciting experiments that became possible since the development of robust 
and highly efficient editing technologies in hPSCs is to genetically and functionally test the 
onslaught of empirical data generated by GWAS. Similar to the disease-modeling approach, 
genome editing allows us to engineer variant alleles observed in these studies found to be 
associated with a specific disease in an otherwise isogeneic cellular setting. Phenotypic 
comparison of such cells can reveal how non-coding mutations, enhancer polymorphisms, 
and balancer mutations, can impact tissue type-specific cellular behaviors that are relevant to 
the particular condition.
For example, this approach has been used successfully to identify the molecular principles 
underlying the most frequent non-coding mutations associated with human cancer (Bojesen 
et al., 2013; Fredriksson et al.; Horn et al., 2013; Huang et al., 2013; Killela et al., 2013). 
Genetic engineering of these mutations, which occur in the promoter of the catalytic subunit 
of human telomerase or TERT, revealed that the mutations result in the failure of cells to 
silence TERT transcription upon cellular differentiation and explains how these mutations 
function in tumorigenesis (Chiba et al., 2015).
Gene-correction frequencies in hPSCs are generally much lower than in tumor cell lines 
such as K578 or HCT116 cells that are commonly used for gene editing in cancer cells. A 
very elegant approach to overcome this challenge and to increase the efficiency of 
homology-mediated events in iPSCs was used in experiments that employed zinc finger 
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nucleases to correct mutations in iPSCs derived from patients with alpha trypsin deficiency. 
In these experiments gene targeting efficiencies were increased by the use of a positive 
selection marker that allowed for the efficient isolation of the edited clones and that could 
subsequently be removed without leaving residual genetic material using PiggyBac 
transposition. This editing strategy allowed for the generation of bi-allelic editing events in 
patient-derived iPSCs to restore alpha trypsin enzymatic function in disease-relevant iPSC-
derived hepatocytes in vitro and after xenotransplantation (Yusa et al., 2011).
A similar approach to overcome the challenges associated with the low frequency of gene-
correction events in hPSCs was used to correct point mutations in the beta-globin gene of 
iPSCs derived from patients with sickle cell disease (Zou et al., 2011). In this case a loxP-
site flanked selection cassette that was used to increase the genome editing efficiency 
initially, but was then subsequently removed using Cre-recombinase. This approach results 
in a single residual loxP site in an in intron of the beta-globin gene. Similarly, two 
independent studies demonstrated the SSN can be used to directly correct b-thalassemia 
mutations in patient derived iPSCs and to restore hematopoietic differentiation (Ma et al., 
2013; Xie et al., 2014).
Alternative strategies for increasing editing efficiencies include methods to more efficiently 
detect and subclone cells that have undergone rare editing events (Miyaoka et al., 2014) as 
well as to enhance delivery methods for the nuclease and donor template (Lin et al., 2014). 
An orthogonal approach to simplify the generation of isogeneic hPSC lines was the 
derivation of an inducible Cas9-expressing cell line by editing a Cas9 expression cassette 
into the AAVS1 locus. In this system Cas9 expression can be induced by doxycycline so that 
efficient editing afterwards only requires the expression or delivery of the sgRNA (Gonzalez 
et al., 2014). This system has been used to generate loss of function alleles in EZH2 and to 
demonstrated the effects of haploinsufficeny for EZH2 in hematopoietic differentiation 
(Kotini et al., 2015). Further developments that facilitate the derivation of genome 
engineered iPSC cell lines are protocols that directly combine genome editing with 
reprogramming. Howden et al demonstrated that human fibroblasts could be simultaneously 
reprogrammed and edited resulting in edited iPSCs going through only one single-cell 
cloning event without the need for drug selection (Howden et al., 2015).
Demonstration for how far-reaching the implementation of genome editing in patient-
specific iPSCs can be for disease modeling was demonstrated by editing experiments that 
inserted an inducible Xist lncRNA into chromosome 21 of Down syndrome patient-derived 
iPSCs. Using this approach Jiang et al. showed that ectopic expression of Xist was sufficient 
to transcriptionally suppress the targeted third copy of chromosome 21 and to reverse the 
cellular disease phenotypes in in vitro differentiated cells (Jiang et al., 2013).
Since the implementation of genome editing in hPSCs several diseases have been modeled 
using isogenic cell lines that have either corrected a disease-relevant mutation in iPSCs or 
introduced a disease relevant allele in wild-type hPSCs. For example, the genetic correction 
of mutations in Niemann-Pick Type C patient-specific iPSCs to rescue metabolic defects in 
cholesterol metabolism and autophagy, which are responsible for the pathology, represents 
just one demonstration of how this approach has been successfully implemented (Maetzel et 
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al., 2014). Furthermore, genome editing in hPSCs has been used to establish models for 
Rett-syndrome disrupting MECP2 function in hPSCs (Li et al., 2013), to generate HIV-
resistant variants alleles of the CCR5 gene into iPSCs (Ye et al., 2014), to repair MYO15A 
in iPSCs derived from patients affected by deafness (Chen et al., 2016) and to derive 
isogeneic cell pairs of COL7A1-corrected iPSCs derived from patients with dystrophic 
epidermolysis bullosa (Sebastiano et al., 2014).
In a growing number of cases, such approaches have also been used to provide new insight 
into disease pathology. For example, SSN-mediated correction of disease-causing mutations 
in LRKK2 that are associated in Parkinson’s disease revealed the transcriptional changes 
caused by disease-associated alleles in patient cells (Reinhardt et al., 2013). Likewise, 
genome editing of patient-specific iPSCs followed by in vitro differentiation was also used 
to generate an isogenic disease model for cystic fibrosis by correcting disease-relevant 
mutations in CFTR followed by differentiation into airway epithelium (Crane et al., 2015; 
Firth et al., 2015; Suzuki et al., 2016).
The challenge of studying sporadic (polygenic) diseases
The application of iPSC technology for the study of sporadic diseases poses particular 
challenges because disease-specific phenotypic changes are expected to be subtle. The 
genetic basis of sporadic or idiopathic diseases is thought to be a combination of multiple 
low effect size risk alleles, mostly in regulatory regions such as enhancers, which are 
identified by GWAS (Gibson, 2011; Merkle and Eggan, 2013). The “common disease-
common variant hypothesis” proposes that multiple risk variants with small effect size in 
combination with additional environmental factors are the drivers of sporadic diseases. Thus, 
a major challenge of using human-derived cells is that risk variants are not only present in 
patients but also in unaffected individuals, albeit with lower frequency. Thus, individual risk 
variants are not sufficient to cause disease-associated phenotypes in carrier individuals or in 
hiPSCs derived from carriers or patients. While an iPSC isolated from a patient would 
harbor all risk variants that contribute to the disease, any in vitro study to gain mechanistic 
insights is complicated by the high system immanent variability in differentiation into the 
disease-relevant cells (Soldner and Jaenisch, 2012). Another complicating factor is that the 
likely effect of a GWAS-identified risk regulatory allele on the target gene (or genes) would 
be predicted to be subtler than would be expected for monogenic diseases as discussed 
above. Thus, it would be impossible to compare the disease specific cells to a suitable 
control cell line because any control cells would have a different genetic background which 
will affect the differentiation potential of the cells and thus would prevent a meaningful 
comparison.
Thus, a major challenge for using iPSCs for the study of sporadic diseases is how to 
generate pairs of isogenic cells that differ at one or multiple risk alleles. Figure 3 outlines a 
possible strategy of how the CRISPR/Cas9 gene editing approach could be used to generate 
isogenic cells that differ at multiple risk loci and thus would enable the mechanistic study of 
polygenic diseases. This approach was recently used to decipher the impact of Parkinson 
disease (PD)-associated risk variants. Genetic engineering of a common PD-associated risk 
variant in a non-coding distal enhancer resulted in deregulation of SNCA expression, a key 
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gene implicated in the pathogenesis of PD, by as little as 10% (Soldner et al, 2016). In order 
to detect such subtle gene expression differences, an allele-specific assay was developed that 
allowed the analysis of cis-acting effects of candidate variants on allele-specific gene 
expression as a consequence of deletion or exchange of disease-associated regulatory 
elements. Detailed analysis of isogenic cells with and without the risk allele further 
demonstrated that a single base pair change causes loss of transcription factor-binding sites 
for the transcription factors that otherwise function as a suppressor of SNCA-transcription 
on a non-risk associated allele.
Epidemiology and population genetics suggest that Sporadic Alzheimer Disease (SAD) 
results from complex interactions between genetic risk variants and environmental factors. 
In another approach to study risk alleles, patient-derived hiPSCs were used to dissect the 
effect of a common SAD-associated non-coding genetic variants in the 5′ region of the 
SORL1 (sortilin-related receptor, L(DLR class) A repeats containing) gene involved in 
intracellular vesicular trafficking (Young et al., 2015). While initial experiments did not 
identify a consistent correlation between SORL1 expression and either disease status or risk 
haplotype, a small but significant correlation between the SAD-associated SORL1 haplotype 
and the BDNF-dependent response of SORL1 expression was found.
Nuclease specificity and off-target considerations
SSNs are enzymes that are targeted to specific site in the genome, but their specificity can 
vary and promiscuous binding to so called off-target sites can lead to unwanted cutting and 
modifications. Strategies to predict, identify, and reduce these off-target events are largely 
dependent on the SSN design, organism, and cell type and have already been to some extent 
implemented in hPSCs. Understanding the frequency and impact of off-targets is highly 
relevant to develop the use of SSN for clinical applications as well as for their reliable use in 
basic research (Gabriel et al., 2011).
Several studies recently addressed the specificity of Cas9 and its off-target action (reviewed 
in (Wu et al., 2014a)). Genome-wide binding studies of dCas9 expressed in mouse ESCs 
demonstrated that Cas9 can associate with a large number of genomic sites, but off-target 
cutting of the catalytically active Cas9 at a subset of these site was infrequent (Wu et al., 
2014b). Similarly, single molecule imaging of Cas9 in living cells have demonstrated that 
Cas9 searches for target sites by three-dimensional diffusion, and that in contrast to on-target 
events off-target binding events are, on average, short-lived (<1 second) (Knight et al., 
2015).
While these data argue for the high specificity of Cas9, data in cancer cells suggest that off-
targets can be frequently detected (Frock et al., 2015; Fu et al., 2014; Tsai et al., 2015; Wang 
et al., 2015b). For example, when using GUIDE-Seq (Tsai et al., 2015), a protocol optimized 
in U2OS and HEK293 to detect off-targets more reliable than other methods such as ChIp-
seq, found many off target that computational algorithms failed to predicted. Based on these 
data sets Tsai et al proposed that shorter guide sequences that only have about 17nt 
homology to the target sequence would improve specificity (Fu et al., 2014). Moreover, the 
GUIDE-Seq. protocol was also used to engineer CRISPR-Cas9 nucleases with altered PAM 
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specificities (Kleinstiver et al., 2015a; Kleinstiver et al., 2015b) and reduced off-targets 
(Kleinstiver et al., 2016).
An alternative protocol called BLES-seq that is based on directly labeling the DSBs 
generated by the nuclease in situ followed by enrichment through streptavidin affinity 
purification and next-generation sequencing (Crosetto et al., 2013) was originally developed 
to detect DSBs caused by replicative stress by stalled replication folks in HeLa cells and 
mouse B lymphocytes. This protocol was further developed to assess Cas9 off-target 
frequencies of Cas9 and to rationally engineer Cas9 nucleases with improved specificity 
(Ran et al., 2015; Slaymaker et al., 2016).
Most experiments that have detected significant off-targets have been performed in cancer 
cells, which may have altered repair pathways that could affect recombination (Fu et al, 
2013; Hsu et al, 2013). In contrast, experiments in whole organisms such as mice ((Wang et 
al., 2013), primates (Niu et al., 2014), Zebrafish (Auer et al., 2014) or C. elegans (Dickinson 
et al., 2013) reported off-target frequencies that were low or not detectable consistent with 
high specificity of the CRISPR/Cas9 mediated gene targeting. It is also possible that in non-
transformed cells off-target cleavages are efficiently counter-selected by the endogenous 
DNA-damage response. As hPSCs are primary cells with genetically intact check-points it 
seems possible that off-targets will accumulate less frequently in hPSCs than it has been 
observed in cancer cells. To address this it will be important to determine to what extent of-
targets are the result of impaired checkpoint control of cancer cells and whether there are 
specific cell-types and conditions that predispose for the accumulation of off-targets. Data 
form conventional whole genome sequencing of hPSCs exposed to Cas9 have so far been 
limited and not yet fully address the issues due to small sample sizes (Park et al., 2015; 
Smith et al., 2014).
Understanding how to avoid off-target SSN modification is of particular concern for the 
eventual clinical application of edited cells. For basic research, however, it seems that the 
necessary experiments are readily available to control for the effects of eventual off-target 
action of SSNs. Experiments to adequately address off-target concern include: (1) the use 
several independent guide RNAs to generate a mutant cell line, (2) complementation of loss-
of-function phenotypes, (3) secondary editing to the mutant cell line to revert the mutation to 
wild-type allele followed by confirmation of phenotypic rescue.
Large-scale screens, epigenetic editing and other applications for Cas9 is 
iPSCs
In addition to allowing for easy, fast, and inexpensive editing of hPSCs the advent of Cas9 as 
a programmable DNA-binding protein allowed for the development of forward genetics 
methodologies that were previously not readily available in hESCs. It is trivial to multiplex 
guide RNA synthesis allowing for the generation of large barcoded libraries of sgRNAs with 
several fold coverage of every gene in the human genome. These libraries can be employed 
in loss-of-function screens, for example, to identify gene products that are required for drug 
resistance or to mediate viral cell death (Gilbert et al., 2014; Hart et al., 2015; Parnas et al., 
2015; Shalem et al., 2014; Shi et al., 2015; Wang et al., 2015a; Wang et al., 2014a; Zhou et 
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al., 2014) (Figure 2). Most of the experiments that employ genome-wide screens have been 
done in cancer cells that can be expanded to accommodate the large numbers of cells that are 
required to perform these type of genome-wide screens. For the general implementation of 
these screening approaches in hPSCs or cells differentiated form hPSCs it will be important 
to develop protocols that allow the expansion of these cells into large homogenous 
populations that allow robust selection or enrichment for cellular phenotypes.
It is worth mentioning that the combination of iPSCs and genome editing has not only 
become a game changer for our approaches to human disease modeling but also provides an 
unprecedented opportunity to study the fundamental principles of cell biology. Previously, 
cell biologists mostly used aberrant cancer cell lines with often unstable and poorly defined 
genomes to describe human cellular behavior. This is mainly because human cancer cells 
presented the only reliable source of human immortal cells that could be expanded 
sufficiently to facilitate biochemical and genetic experimentation and that could be 
indefinitely propagated, frozen, shipped, and shared between labs. This monopoly of cancer 
cells as a model system was broken with the advent of hiPSCs and the general availability of 
hPSCs. Like cancer cells, hPSCs are immortal, but they do not suffer from the disadvantages 
of the pathologically altered genomes of cancer cells and yet they still retain the capacity to 
differentiate into any cell type of interest. The combination of hPSCs with the power of 
genome editing can now be used to study the specific aspects of human cell biology. 
Exploiting this potential will be particularly important in areas of research where 
fundamental biological processes diverge between human and other species such as tumor 
suppression, and cellular immortality, or neuronal biology. Efforts such as the one launched 
by the Allen Institute for Cell Science to create an industrial scale library of characterized 
iPSCs that will be used to create a visual, animated model of the cell, suggest that iPSCs will 
soon replace cancer cells as a model system for basic cell biology (Callaway, 2014).
In the same way that iPSC technology had broad impacts far beyond regenerative medicine 
and disease modeling, the impact of the discovery of CRISPR/Cas9 on hPSCs is not only its 
ability to act as a SSN. Catalytically inactive forms of Cas9 (dCas9) have been successfully 
derived by fusions with functional protein that bind specific loci, or to activate or repress 
gene activity at the target site (Chen et al., 2013; Gilbert et al., 2014; Konermann et al., 
2015; Mandegar et al., 2016; Tanenbaum et al., 2014) (CRISPRa and CRISPRi, Figure 2). 
Some of these platforms have been successfully implemented for genome-wide screens and 
to manipulate hPSCs. As demonstrated for TALE proteins and Zinc finger DNA binding 
domains, the range of Cas9 could be extended in the future to also methylate or demethylate 
DNA or histones/chromatin at precise locations in the genome (Maeder et al., 2013; Meister 
et al., 2010). Moreover, dCas9 fused to fluorescent reporters have been developed to indicate 
nuclear organization by visualizing individual genomic loci (Chen et al., 2013; Gilbert et al., 
2014; Tanenbaum et al., 2014). Excitingly more applications are being developed; recently 
Cas9 has now also been programmed to target RNA in vitro and in vivo (O’Connell et al., 
2014) (Nelles et al., 2016), raising the possibly that it could be used to better understand the 
transcriptome in addition to the genome.
Arguably the most far-reaching consequence of CRISPR/Cas9 gene targeting is the potential 
to edit the germ line. Because gene editing by homologous recombination is inefficient, cells 
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carrying the desired targeting event need to be selected in culture. Thus, germ line 
modification in the past was restricted to mice as chimera-competent ES cells are not 
available in other species. Because CRISPR/Cas9 gene editing is so efficient, it requires no 
selection for the desired targeting events rendering ES cells superfluous for the generation of 
mutant animals. CRISPR/Cas9 enabled gene editing in the zygote and was used to 
efficiently generate animals carrying defined mutations in multiple species including fish, 
drosophila, mice and primates (Bassett et al., 2013; Chang et al., 2013; Gratz et al., 2013; 
Hwang et al., 2013a; Hwang et al., 2013b; Niu et al., 2014; Wang et al., 2013; Yang et al., 
2013; Yu et al., 2013).
Challenges and next steps
Despite the obvious advances that have been made as a result of iPSC and editing 
technologies, several challenges remain. A key limitation remains that human cells prefer to 
choose the imprecise NHEJ pathway to repair a DSB rather than using the more precise 
homologous DNA repair pathway using an exogenous repair template (Chapman et al., 
2012). Due to this pathway choice, editing events often result in NHEJ-mediated insertions 
and deletions at the DSB rather than the intended homology mediated modification. NHEJ-
mediated gene disruption can be useful when the researcher or clinician intends to generate a 
loss-of-function event. However, in most clinical treatment settings the generation of a 
defined allele with high frequency will be essential to devise treatment options that require 
editing to result in gain-of-function at endogenous genes. Approaches to shift the balance 
away from NHEJ and towards homology-mediated repair included NHEJ inhibition with 
small molecules or by controlling the timing of CRISPR/Cas9 delivery with respect to the 
cell cycle stage (Chu et al., 2015; Maruyama et al., 2015; Robert et al., 2015; Yu et al., 
2015). These approaches are promising, yet we are currently far away from testing the 
efficacy of treatment strategies that rely on gene repair or gain-of-function approaches using 
high frequency HR repair events of endogenous genes.
Facing this challenge, recent studies used creative ways to take advantage of NHEJ-
meditated genome editing and the fact that the simultaneous expression of two nucleases can 
meditate the excision or inversion of the sequence internal to the two SSN (Chiba et al., 
2015; (Chen et al., 2011; Young et al., 2016). In the specific case of Duchenne muscular 
dystrophy, Cas9 was employed to excise 725 kb of genomic sequences, which removed a 
premature STOP codon in the disease-causing DMD gene and thereby restored the reading 
frame and partial protein function (Young et al., 2016).
Similarly, Cas9 mediated genome editing in patient specific iPSCs was used to genetically 
correct the disease causing chromosomal inversions found in patients with Hemophilia A, 
demonstrating that NHEJ based approaches can be used to model and correct large scale 
genomic alterations underlying human disease (Park et al., 2015).
Elegant work that also takes advantage of the fact that genomic sequences between two SSN 
cuts can reinsert into back into the locus in an inverted manner was recently used 
demonstrated that CTCF sites interact with each other in an orientation dependent manner 
(Guo et al., 2015). Using this approach Guo et al elucidate the impact of the directionality of 
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CTCF sites in the mediation of large-scale genome interactions and transcriptional 
regulation.
Another challenge of genome editing in human cells is that human cells have relatively short 
conversion tracts (Elliott et al., 1998). This means that even when a DSB is repaired by 
homology directed repair and not the NHEJ machinery, modifications can only be made with 
reasonable frequency very close to one side of the double stranded break. This presents a 
major obstacle towards the introduction of complex genetic changes in hPSCs. The use of 
Cpf1, a class 2 CRISPR effector that uses the same basic principles as Cas9, but cleaves 
DNA further away from the PAM sequence and generates a single stranded overhang, may 
help increase the rate of HDR over NHEJ events (Zetsche et al., 2015). Overcoming this 
challenge will significantly facilitate the engineering of human stem cells, as it will allow us 
to refine the human genome more efficiently. Eventually this could result in similar 
resources that have been used in yeast and mESCs, such as a comprehensive collection of 
conditional human knockout iPSC libraries, with a homozygous iPSC line for each human 
gene carrying an exon flanked by loxP sites.
Rethinking the ethical debate
It will be important in the near future to navigate the ethical debate that arises from the 
confluence of genome editing with stem cell technology. This requires a policy framework 
that supports scientific progress that is independent of special interest groups that would bias 
a rational risk benefit assessment of this technology. The rampant progress that has been 
made over the last few years to improve genome editing technologies and to detect and 
reduce potential off-targets of SSNs has already lead to the first clinical trials for HIV and 
are trail blazing through the necessary regulatory hurdles (Tebas et al., 2014). Somatic cell 
editing and editing in hPSCs in vivo and/or ex vivo coupled with transplantation will 
progress to become a standard clinical application. These efforts have to be clearly 
distinguished from editing human germ cells or totipotent cells of the early human embryo. 
Indeed, the efficiency of altering the genome of mammals by injecting CRISPR/Cas9 RNA 
or DNA into the fertilized egg (Wang et al, 2013) sparked a debate whether this technology 
should be used to modify the human germ line (Sheridan, 2015). While technical challenges 
currently limit the potential application of such modifications, two recent papers describe 
gene editing of the embryo’s genome following injection of gRNAs, CRSPR/Cas9 RNA and 
targeting oligos into human zygotes (Kang et al., 2016; Liang et al., 2015). These studies 
raise a number of scientific issues such as off-target rate, mosaicism and the likely alteration 
of the non-targeted wild type allele when targeting a mutant allele. More importantly, the 
technology raises serious ethical issues: do we want to irreversibly alter the human germ 
line? Thus, the clinical application of this gene editing technology for medical purposes 
raises important ethical issues that will need to be widely discussed and agreed upon as it 
would affect future generations.
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Figure 1. Overview of the iPSC technology
Patient cells can be reprogrammed into iPSCs using optimized reprogramming protocols that 
involve small molecules, microRNAs, and combinations of reprogramming factors. iPSCs 
can be differentiated into somatic cells that could be used either in transplantation therapies 
or alternatively to model human diseases.
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Figure 2. Genome editing applications in hiPSCs
Genome editing allows for the genetic modification of hiPSCs. The top panel (left side) 
depicts examples of reverse genetic approaches to study hPSCs using genome editing. Gene 
expression can be modulated (activated or repressed: CRISPRi and CRISPRa) by reversibly 
targeting their endogenous promoter. Genes can be inserted to generate reporter genes or to 
achieve ectopic expression. Genetic information can be deleted or inverted and modifications 
as small as single base pairs changes can be generated to introduce mutations, 
polymorphisms or repair disease relevant mutations. The resulting genetically engineered 
hPSCs differ from wild type cells exclusively at the edited locus and are otherwise isogenic 
(bottom left). Parallel differentiation of these isogenic cell lines into disease relevant cell-
types can provide the basis for the phenotypic analysis of disease specific cellular 
pathologies. Phenotypes found in these cells can be directly attributed to the genetic 
manipulation. In addition, forward genetic approaches to study hPSCs (top right panel) 
became available with the development of genome editing as a screening tool. Bulk 
transduction of hPSCs with either Cas9 or dCas9 in combination with genome wide 
barcoded sg RNA libraries --“CRISPR cutting, CRISPRi and CRISPRa”—can be used to 
identify genes who’s loss- or gain-of-function changes the cellular representation within the 
infect cell pool. Enrichment or depletion of sgRNAs can be determined by sequencing of the 
sgRNAs, yielding candidate genes of interest (bottom right panel).
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Figure 3. 
Strategy to generate isogenic iPSCs that differ at multiple risk alleles. GWAS have identified 
genomic loci that may slightly increase the risk of developing a sporadic disease. The key 
challenge of using patient-derived iPSCs to get mechanistic insight into risk alleles is to 
create meaningful control cells. CRISPR/Cas9 mediated gene editing would allow to 
exchange risk (red squares) and protective (green squares) alleles and to generate 
appropriate control cells that differ exclusively at the risk loci under study.
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